
Vor Biopharma rose 89.3% from $10.02 to $18.97, ahead of the S&P 500's +11.2%. Its worst day was Nov 19 (−14.3%), and its low came Nov 20 at $6.86.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Vor Biopharma closed at its lowest level of the year, 31.5% below where the year started.
−12.3% · S&P 500 −1.5%
Vor Biopharma shares rose 28.2%, while the S&P 500 fell 0.1%.
Story events cover the past 12 months · Times ET
+28.2%, the year's best day, on 42M shares, the year's heaviest volume · S&P 500 −0.1%
Vor Biopharma shares rose 16.2%, while the S&P 500 fell 0.3%.
+16.2% · S&P 500 −0.3%
EPS of $-1.63 missed the $-1.14 estimate on $0.00 revenue.
+1.5% · S&P 500 −0.3%
EPS of $-0.73 beat the $-0.78 estimate on $0.00 revenue.
−3.4% · S&P 500 +0.6%
Vor Biopharma shares rose 15.5%, while the S&P 500 rose 1.6%.
+15.5% · S&P 500 +1.6%
Vor Biopharma shares rose 14.9%, while the S&P 500 rose 0.8%.
+14.9% · S&P 500 +0.8%
EPS of $-0.80 missed the $-0.70 estimate on $0.00 revenue.
+0.9% · S&P 500 −0.3%
Vor Biopharma closed at its highest level of the year, 150.5% above where the year started.
+0.2% · S&P 500 −0.5%
EPS of $-0.90 missed the $-0.74 estimate on $0.00 revenue.
−5.9% · S&P 500 −1.8%
Where it ended: a close of $18.97 on Nov 16, 2026.
Nothing in the past 12 months.
All VOR dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for VOR and SPY from Benzinga historical bars. Not investment advice.